Abstract: Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators de- rived from arachidonic acid through the 5-lipoxy- genase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). Published evidence justifies a broader role for LT receptor antagonists (LTRAs), in particular, montelukast, in the treatment of bronchial asthma, allergic rhinitis, and recently, in cardiocerebrovas- cular disease. The actions of Cys-LTs on the car- diovascular (CV) system are well-documented and include a broad array of activities with promising therapeutic targets in animal models exploring the use of selective 5-LO (or 5-LO-activating protein) inhibitors or dual LO-cycloxygenase-blocking agents in experimentally induced acute myocardial infarction. The picture that emerges from studies with LTRAs is more controversial at the moment, and some findings suggest a role for Cys-LTs in the extension of ischemic damage and in cardiac dys- function during reperfusion; others do not. The aim of this short review is to summarize the state of present research about LT modifier treatment in CV disease.
Leukotriene modifiers in the treatment of cardiovascular diseases.
D'ORAZIO, Nicolantonio;BUCCIARELLI, Tonino;
2008-01-01
Abstract
Abstract: Cysteinyl-leukotrienes (Cys-LTs) and LTB4 are potent proinflammatory mediators de- rived from arachidonic acid through the 5-lipoxy- genase (5-LO) pathway, which exerts important pharmacological effects through their interaction with specific receptors: Cys-LT receptors (CysLT1 and CysLT2) and LTB4 receptors (BLT1 and BLT2). Published evidence justifies a broader role for LT receptor antagonists (LTRAs), in particular, montelukast, in the treatment of bronchial asthma, allergic rhinitis, and recently, in cardiocerebrovas- cular disease. The actions of Cys-LTs on the car- diovascular (CV) system are well-documented and include a broad array of activities with promising therapeutic targets in animal models exploring the use of selective 5-LO (or 5-LO-activating protein) inhibitors or dual LO-cycloxygenase-blocking agents in experimentally induced acute myocardial infarction. The picture that emerges from studies with LTRAs is more controversial at the moment, and some findings suggest a role for Cys-LTs in the extension of ischemic damage and in cardiac dys- function during reperfusion; others do not. The aim of this short review is to summarize the state of present research about LT modifier treatment in CV disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
